Cancer Research
Data from preclinical studies in collaboration with Fred Hutchinson Cancer Research Center will be presented at ASH and provide strong rationale for use of EOS-448 as a single agent and in combination with an immunomodulatory drug in patients with multiple myeloma Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for multifaceted mechanism of…
Read More
New DESTINY-Breast03 data presented at SABCS 2021 showed AstraZeneca and Daiichi Sankyo’s ENHERTU demonstrated a similar benefit in patient subgroups, including in patients with stable brain metastases, versus T-DM1 Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–New results from the DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki)demonstrated a higher progression-free survival (PFS) and objective…
Read More
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented Excerpt from the Press Release: PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for…
Read More
Excerpt from the Press Release: DUBLIN, Ireland and BOSTON, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today at the 2021 San Antonio Breast Cancer Symposium (SABCS), presented encouraging clinical data on samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, that support its…
Read More
— Collaboration leverages imaging, diagnostic and multiomic expertise to identify new, significant biomarkers to improve the detection of breast cancer Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 1, 2021 /PRNewswire/ — Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify…
Read More
Lungs among most common site for metastatic tumors Excerpt from the Press Release: HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, Inc., a therapeutic oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its biology-guided radiotherapy* (BgRT) for use in treating lung tumors. The breakthrough potential of BgRT lies…
Read More
Funding provides $16 million in support for Ontario cancer research Excerpt from the Press Release: December 2, 2021—Toronto—Today the Ontario Institute for Cancer Research (OICR) announced funding for 16 studies as part of the Institute’s new Clinical Translation Pathway (CTP). These awards support pre-clinical research and new clinical trials that have a focus on early…
Read More December 1, 2021—Toronto— Today the Ontario Institute for Cancer Research (OICR) announced renewed funding for its Adaptive Oncology (AO) research theme, which includes funding for three new research projects with the potential to have rapid clinical impact. Excerpt from the Press Release: he Adaptive Oncology theme was developed to anticipate and counter tumour evolution and…
Read More- « Previous
- 1
- …
- 29
- 30
- 31